Search

everythinglearnresearchcommunity

for

Search:↓

A 37-year-old man is seeking advice for hair loss treatment, considering options like finasteride and topical or oral minoxidil. A user suggests consulting a doctor and monitoring blood pressure if using oral minoxidil.

Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.

The user is struggling with hair loss and has tried treatments like finasteride, minoxidil, and dutasteride without success, considering a hair transplant as a future option. Others suggest focusing on mental health and self-worth beyond physical appearance, while some share their own experiences with similar treatments and outcomes.

Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.

A trans man experiencing hair loss after starting testosterone treatment has seen positive results using topical minoxidil and finasteride, though his hair remains thin. He is considering continuing his current treatment and exploring additional options like microneedling and Breezula, while acknowledging the impact of testosterone on hair loss.

Topical spironolactone is gaining attention as an alternative hair loss treatment, but it's not as effective as other options like finasteride. Oral spironolactone can cause side effects in men, and there are better topical alternatives like RU, Pyril, and CB.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

A 19-year-old is concerned about using low-dose sublingual minoxidil for hair loss and its potential side effects, while questioning its effectiveness against DHT. They are considering whether this treatment is the best option.

Topical formulations, natural products, and CAM therapies are being used to treat Androgenic alopecia to avoid side effects of Finasteride and Minoxidil. The review covers various low-risk, alternative treatment options.

An 18-year-old using finasteride since February and minoxidil since July has not seen improvement in hair density. They are advised to continue treatment as results can take up to a year, and to consider other options if no change occurs after a full year.

A 23-year-old experiencing severe diffuse thinning after scalp inflammation is considering finasteride as a last resort after stopping minoxidil and using anti-inflammatory medication. Users suggest that inflammation causes temporary shedding and recommend consulting a dermatologist, with some advocating for finasteride as a reliable treatment option.

A user is experiencing hair loss in the center of their hairline and has been using topical finasteride for seven months with minimal progress. They are considering switching treatments due to concerns about losing ground and potential side effects of other options.

People are hopeful for a permanent hair loss solution by the 2030s, considering options like hair cloning and treatments like pp405. Synthetic hair transplants have been attempted but are not effective long-term.

A user who underwent a hair transplant in their twenties and are now discussing the best treatments for long-term management of hair loss, such as finasteride and Minoxidil, as well as potential alternative treatment options like RU58841.

Hair loss can cause psychological distress, but maintaining optimism and self-improvement is crucial. Treatments like minoxidil, finasteride, and potential new options like clascoterone offer hope, though side effects can occur.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

The individual is struggling with hair loss and depression, having tried treatments like Finasteride, Dutasteride, and Minoxidil, but faced side effects and limited success. They are considering a hair transplant and other options while dealing with personal challenges, including knee injuries and weight issues, and are encouraged by others to focus on self-improvement and acceptance.

The conversation discusses the effectiveness of anti-androgens for hair loss, with a preference for topical treatments like RU58841 over oral options due to better scalp concentration and fewer side effects. Topical finasteride at 0.1% may provide some results, especially when combined with a topical androgen receptor antagonist like RU58841.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.

The user experienced stable hairline but diffuse thinning after switching from oral finasteride to a topical solution of minoxidil and finasteride. They are concerned about the effectiveness of the topical treatment and are considering other options due to a recent decline in hair density.

There is no imminent cure for hair loss, but treatments like Minoxidil, Finasteride, and new drugs such as KX-826, GT-20029, and PP405 are being explored. Current solutions focus on slowing hair loss and stimulating growth, with hopes for better options in the future.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

Stemoxydine may work synergistically with minoxidil and finasteride for hair growth, but its effectiveness is debated, with some users experiencing minimal results and concerns about cost. Users suggest sticking to proven treatments like minoxidil and finasteride, while considering stemoxydine as an additional option.

A user shared their 11-year experience with spironolactone and nearly 5 years with finasteride for hair loss, recently adding oral minoxidil and stopping birth control. Various treatments were discussed, including organic options, checking for underlying health issues, considering dutasteride, and the potential role of progesterone in hair loss.

An 18-year-old is experiencing severe hair loss and dandruff, feeling stressed and unable to commit to Minoxidil or handle finasteride side effects. They have tried natural oils, anti-hair fall shampoo, and consulted a dermatologist without success, and are seeking affordable treatment options.

The user regrets not using medication after a failed hair transplant and is now using a combination of minoxidil, finasteride, derma rolling, oils, and ketoconazole shampoo to try to improve hair regrowth. They are seeking feedback on progress and considering further treatment options.

OP is considering Bicalutamide for female AGA and TE but is concerned about its side effects and effectiveness compared to Finasteride. OP is also using Minoxidil and Spironolactone but is experiencing significant shedding and is unsure if it's androgen-driven or due to Minoxidil changes.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

A 21-year-old male has been on a hair loss treatment for 6 months using finasteride, oral minoxidil, and ketoconazole shampoo, with slight improvement noted by his dermatologist. He is considering adding topical spironolactone, switching to dutasteride, increasing minoxidil dosage, or trying PRP injections for better results.